4.6 Article

Outcomes of Influenza A(H1N1)pdm09 Virus Infection: Results from Two International Cohort Studies

期刊

PLOS ONE
卷 9, 期 7, 页码 -

出版社

PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0101785

关键词

-

资金

  1. Leidos Prime [HHSN261200800001E]
  2. NCI/NIAID
  3. Medical Research Council [MC_UU_12023/16, MC_U122886352] Funding Source: researchfish
  4. MRC [MC_U122886352, MC_UU_12023/16] Funding Source: UKRI

向作者/读者索取更多资源

Background: Data from prospectively planned cohort studies on risk of major clinical outcomes and prognostic factors for patients with influenza A(H1N1)pdm09 virus are limited. In 2009, in order to assess outcomes and evaluate risk factors for progression of illness, two cohort studies were initiated: FLU 002 in outpatients and FLU 003 in hospitalized patients. Methods and Findings: Between October 2009 and December 2012, adults with influenza-like illness (ILI) were enrolled; outpatients were followed for 14 days and inpatients for 60 days. Disease progression was defined as hospitalization and/or death for outpatients, and hospitalization for >28 days, transfer to intensive care unit (ICU) if enrolled from general ward, and/or death for inpatients. Infection was confirmed by RT-PCR. 590 FLU 002 and 392 FLU 003 patients with influenza A(H1N1)pdm09 were enrolled from 81 sites in 17 countries at 2 days (IQR 1-3) and 6 days (IQR 4-10) following ILI onset, respectively. Disease progression was experienced by 29 (1 death) outpatients (5.1%; 95% CI: 3.4-7.2%) and 80 inpatients [death (32), hospitalization >28 days (43) or ICU transfer (20)] (21.6%; 95% CI: 17.5-26.2%). Disease progression (death) for hospitalized patients was 53.1% (26.6%) and 12.8% (3.8%), respectively, for those enrolled in the ICU and general ward. In pooled analyses for both studies, predictors of disease progression were age, longer duration of symptoms at enrollment and immunosuppression. Patients hospitalized during the pandemic period had a poorer prognosis than in subsequent seasons. Conclusions: Patients with influenza A(H1N1)pdm09, particularly when requiring hospital admission, are at high risk for disease progression, especially if they are older, immunodeficient, or admitted late in infection. These data reinforce the need for international trials of novel treatment strategies for influenza infection and serve as a reminder of the need to monitor the severity of seasonal and pandemic influenza epidemics globally.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Immunology

Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial

Rocio Montejano, Fernando de la Calle-Prieto, Maria Velasco, Carlos Guijarro, Javier Queiruga-Parada, Maria Jimenez-Gonzalez, Patricia Gonzalez-Ruano, Patricia Martinez, Ane Josune Goikoetxea, Marta Ibarrola, Marianela Ciudad, Angela Gutierrez, Miguel Torralba, Ana Diaz-Brasero, Pablo Ryan, Cristina Marcelo, Cristina Diez, Sofia Ibarra, Esperanza Merino, Vicente Estrada, Javier Marcos, Maria Novella, Maria A. Rivera, Manuel Ruiz-Munoz, Marta de Miguel, Llanos Soler, Mikel Del Alamo, Santiago Moreno, Antonio J. Carcas, Alberto M. Borobia, Jose R. Arribas

Summary: This study aimed to evaluate the effectiveness of tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) treatment in high-risk patients with severe COVID-19. The results showed that TDF/FTC did not provide significant benefits, while the beneficial effect of baricitinib, as established by prior clinical trials, was confirmed.

CLINICAL INFECTIOUS DISEASES (2023)

Article Clinical Neurology

Myopathy as a cause of Long COVID fatigue: Evidence from quantitative and single fiber EMG and muscle histopathology

Jane Agergaard, Benjamin Yamin Ali Khan, Thomas Engell-Sorensen, Berit Schiottz-Christensen, Lars ostergaard, Eva K. Hejbol, Henrik D. Schroder, Henning Andersen, Jakob Udby Blicher, Thomas Holm Pedersen, Thomas Harbo, Hatice Tankisi, M. U. L. T. I. C. O. V. Consortium MULTICOV Consortium

Summary: This study examined 84 patients with long COVID using qEMG and sfEMG, and performed muscle biopsies in a subset of patients. The results showed that the mean MUP duration was decreased in >= 1 muscles in 52% of the patients, and the mean jitter was increased in 17% of the patients in the tibialis anterior and 25% in the extensor digitorum communis. Muscle biopsies revealed damage of terminal nerves and motor endplate with abundant basal lamina material. These findings suggest a muscle pathophysiology behind fatigue in long COVID.

CLINICAL NEUROPHYSIOLOGY (2023)

Article Respiratory System

Faster lung function decline in people living with HIV despite adequate treatment: a longitudinal matched cohort study

Rebekka Faber Thudium, Andreas Ronit, Shoaib Afzal, Yunus Colak, Julie Lyng Forman, Fernando Mendo, Fabian Chen, Vicente Estrada, Nagalingeswaran Kumarasamy, Borge G. Nordestgaard, Jens Lundgren, Jorgen Vestbo, Ken M. Kunisaki, Susanne Dam Nielsen

Summary: This study compared the decline in lung function between people living with HIV who receive antiretroviral therapy and matched controls, and found that well-treated PLWH have faster lung function decline than controls. Smoking seems to modify this association, suggesting that smoking may lead to more rapid lung function decline in PLWH than in controls.

THORAX (2023)

Review Chemistry, Medicinal

Bulevirtide in the Treatment of Hepatitis Delta: Drug Discovery, Clinical Development and Place in Therapy

Vicente Soriano, Victor Moreno-Torres, Ana Trevino, Octavio Corral, Carmen de Mendoza

Summary: It has been ten years since the identification of NTCP as the cell surface receptor for HBV and HDV entry into hepatocytes. Bulevirtide (BLV) has been developed as a potential inhibitor of NTCP-HBV/HDV binding and has shown promising results in preclinical and clinical studies. Combination therapies with BLV and other anti-HBV/HDV agents are expected to lead to a cure for hepatitis delta in the near future.

DRUG DESIGN DEVELOPMENT AND THERAPY (2023)

Article Infectious Diseases

Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses

Rodrigo Alonso-Navarro, Margarita Ramirez, Mar Masia, Roger Paredes, Rocio Montejano, Marina Povar-Echeverria, Jordi Carratala, Miguel Salavert, Enrique Bernal, Carlos Duenas, Juan Flores, Francisco Fanjul, Isabel Gutierrez, Veronica Rico, Lourdes Mateu, Julen Cadinanos, Juan Berenguer, Alex Soriano

Summary: This study evaluated the variables associated with the need for ICU admission in COVID-19 patients receiving remdesivir, including the duration from symptom onset to remdesivir use. The results showed that a shorter duration from symptom onset to remdesivir use (within 5 days) decreased the risk of ICU admission. Other factors associated with ICU admission included clinical signs of severe disease and the use of corticosteroids and anti-inflammatory drugs.

BMC INFECTIOUS DISEASES (2023)

Letter Medicine, General & Internal

Response to: Prognostic factors in hospitalized HIV-positive patients with COVID-19: correspondence

V Moreno-Torres, V Soriano

QJM-AN INTERNATIONAL JOURNAL OF MEDICINE (2023)

Article Immunology

Association of Self-reported Systemic Reactions Following SARS-CoV-2 Vaccination With Immunological Response in the Danish National Cohort Study of Effectiveness and Safety of SARS-CoV-2 Vaccines (ENFORCE)

Wendy P. Bannister, Dorthe Raben, Palle Valentiner-Branth, Martin Tolstrup, Lykke Larsen, Britta Tarp, Mette Brouw Iversen, Ole Schmeltz Sogaard, Sisse Rye Ostrowski, Nina Breinholt Staerke, Marie Louise Jakobsen, Susan Olaf Lindvig, Maria Ruwald Juhl, Isik Somuncu Johansen, Ahmed B. Mustafa, Lars Ostergaard, Fredrikke Dam Larsen, Lene Surland Knudsen, Vibeke Klastrup, Lothar Wiese, Thomas Benfield, Kristine Toft Petersen, Kasper K. Iversen, Henrik Nielsen, Joanne Reekie, Jens Lundgren

Summary: Concerns about side effects may contribute to vaccine hesitancy, but knowing that SARS-CoV-2 vaccines can lead to a stronger immune response may encourage more individuals to get vaccinated. Severe adverse reactions were associated with a stronger antibody response after the second vaccine dose, but not after the first. Regardless of side effects, most people experienced an effective immune response following vaccination.

OPEN FORUM INFECTIOUS DISEASES (2023)

Article Immunology

The Current Mismatch Between Coronavirus Disease 2019 Clinical Trial Design and the Evolving Profile of Hospitalized Patients: A Retrospective Cohort Analysis

Rocio Montejano, Alfredo Soler-Carracedo, Alberto M. Borobia, Alejandro Martin-Quiros, David Grandioso, Carlos Canada, Alicia Roman, Jose R. Arribas

Summary: An evaluation of 100 hospitalized COVID-19 patients in Madrid revealed a mismatch between current clinical trial designs and the characteristics of the patients, indicating a need to reconsider trial criteria.

CLINICAL INFECTIOUS DISEASES (2023)

Article Virology

Examination of autoantibodies to type I interferon in patients suffering from long COVID

Kristoffer Skaalum Hansen, Sofie Eg Jorgensen, Morten Kelder Skouboe, Jane Agergaard, Berit Schiottz-Christensen, Line Khalidan Vibholm, Martin Tolstrup, Lars Ostergaard, Steffen Leth, Trine H. Mogensen

Summary: Long COVID is an emerging global health concern, and its underlying mechanism and pathophysiology are still unclear. This study found that autoantibodies against type 1 interferons in patients with Long COVID do not contribute to the symptoms.

JOURNAL OF MEDICAL VIROLOGY (2023)

Article Biochemistry & Molecular Biology

Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial

Jesper D. Gunst, Jesper F. Hojen, Marie H. Pahus, Miriam Rosas-Umbert, Birgitte Stiksrud, James H. Mcmahon, Paul W. Denton, Henrik Nielsen, Isik S. Johansen, Thomas Benfield, Steffen Leth, Jan Gerstoft, Lars Ostergaard, Mariane H. Schleimann, Rikke Olesen, Henrik Stovring, Line Vibholm, Nina Weis, Anne M. Dyrhol-Riise, Karen B. H. Pedersen, Jillian S. Y. Lau, Dennis C. Copertino, Noemi Linden, Tan T. Huynh, Victor Ramos, R. Brad Jones, Sharon R. Lewin, Martin Tolstrup, Thomas A. Rasmussen, Michel C. Nussenzweig, Marina Caskey, Dag Henrik Reikvam, Ole S. Sogaard

Summary: In people with HIV-1 undergoing antiretroviral treatment interruption, combining lefitolimod with broadly neutralizing antibodies (bNAbs) did not delay viral rebound beyond that achieved with bNAbs alone, raising the question of how to optimize combination immunotherapy to control HIV-1.

NATURE MEDICINE (2023)

Article Biochemistry & Molecular Biology

Metabolic Profiling Early Post-Allogeneic Haematopoietic Cell Transplantation in the Context of CMV Infection

Kirstine K. Rasmussen, Quenia dos Santos, Cameron Ross Macpherson, Adrian G. Zucco, Lars Klingen Gjaerde, Emma E. Ilett, Isabelle Lodding, Marie Helleberg, Jens D. Lundgren, Susanne D. Nielsen, Susanne Brix, Henrik Sengelov, Daniel D. Murray

Summary: This study investigated the associations between metabolic profiles and cytomegalovirus (CMV) infection after allogeneic hematopoietic stem cell transplantation (aHSCT). The results showed that lower levels of trimethylamine N-oxide were associated with subsequent CMV infection. Exploratory analysis also revealed other metabolic clusters associated with CMV infection.

METABOLITES (2023)

Correction Medicine, Research & Experimental

Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients (vol 2,114, 2022)

Rebecka Svanberg, Cameron MacPherson, Adrian Zucco, Rudi Agius, Tereza Faitova, Michael Asger Andersen, Caspar da Cunha-Bang, Lars Klingen Gjaerde, Maria Elizabeth Engel Moller, Patrick Terrence Brooks, Birgitte Lindegaard, Adin Sejdic, Zitta Barrella Harboe, Anne Ortved Gang, Ditte Stampe Hersby, Christian Brieghel, Susanne Dam Nielsen, Daria Podlekareva, Annemette Hald, Jakob Thaning Bay, Hanne Marquart, Jens Lundgren, Anne-Mette Lebech, Marie Helleberg, Carsten Utoft Niemann, Sisse Rye Ostrowski

COMMUNICATIONS MEDICINE (2023)

Article Immunology

HTLV infection in persons with sexually transmitted diseases in Spain

Oskar Ayerdi, Rafael Benito, Diego Ortega, Antonio Aguilera, Natalia Montiel, Ilduara Pintos, Alberto Diaz de Santiago, Begona Baza, Vicente Soriano, Carmen de Mendoza

Summary: The prevalence of HTLV infection among individuals with STIs in Spain is 0.5%, higher than in the general population. These results suggest the need for universal HTLV screening in individuals attending clinics for STIs.

FRONTIERS IN IMMUNOLOGY (2023)

Article Immunology

Differences in toll-like receptor ligand-induced cytokine concentrations before and after solid organ transplantation: A prospective, observational cohort study in a clinical setting

Dina Leth Moller, Soren Schwartz Sorensen, Michael Perch, Finn Gustafsson, Annemette Hald, Andreas Delhbaek Knudsen, Ranya Abdulovski, Nicoline Stender Arentoft, Jens Lundgren, Allan Rasmussen, Sisse Rye Ostrowski, Susanne Dam Nielsen

Summary: This study investigated the change in induced cytokine concentrations after solid organ transplantation (SOT) and found that all stimuli except IL-10 showed decreased concentrations post-SOT. The study also found no difference in induced cytokine concentrations pre-SOT between recipients with or without acute rejection. This standardized assay may provide important information on immune function post-SOT.

SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2023)

Meeting Abstract Biochemistry & Molecular Biology

Added value of reanalysing whole exome- and whole genome sequencing data with an extended gene panel and structural variant calling in patients suspected of having primary immune deficiency

Sara Morup, Lusine Nazaryan-Petersen, Migle Gabrielaite, Joanne Reekie, Hanne V. Marquart, Hans Jakob Hartling, Rasmus Marvig, Terese L. Katzenstein, Tania N. Masmas, Jens D. Lundgren, Daniel D. Murray, Marie Helleberg, Line Borgwardt

EUROPEAN JOURNAL OF HUMAN GENETICS (2023)

暂无数据